- Home
- SIBN vs PHAT Comparison
SIBN vs PHAT Comparison
Compare SIBN & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIBN
- PHAT
- Stock Information
- Founded
- SIBN 2008
- PHAT 2018
- Country
- SIBN United States
- PHAT United States
- Employees
- SIBN N/A
- PHAT N/A
- Industry
- SIBN Medical/Dental Instruments
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- SIBN Health Care
- PHAT Health Care
- Exchange
- SIBN Nasdaq
- PHAT Nasdaq
- Market Cap
- SIBN 557.9M
- PHAT 539.5M
- IPO Year
- SIBN 2018
- PHAT 2019
- Fundamental
- Price
- SIBN $13.85
- PHAT $8.16
- Analyst Decision
- SIBN Strong Buy
- PHAT Strong Buy
- Analyst Count
- SIBN 7
- PHAT 4
- Target Price
- SIBN $23.43
- PHAT $23.00
- AVG Volume (30 Days)
- SIBN 250.3K
- PHAT 992.3K
- Earning Date
- SIBN 11-12-2024
- PHAT 11-07-2024
- Dividend Yield
- SIBN N/A
- PHAT N/A
- EPS Growth
- SIBN N/A
- PHAT N/A
- EPS
- SIBN N/A
- PHAT N/A
- Revenue
- SIBN $157,035,000.00
- PHAT $26,270,000.00
- Revenue This Year
- SIBN $21.24
- PHAT $7,622.43
- Revenue Next Year
- SIBN $15.59
- PHAT $236.87
- P/E Ratio
- SIBN N/A
- PHAT N/A
- Revenue Growth
- SIBN 18.98
- PHAT N/A
- 52 Week Low
- SIBN $11.70
- PHAT $6.07
- 52 Week High
- SIBN $21.70
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- SIBN 52.66
- PHAT 36.67
- Support Level
- SIBN $13.10
- PHAT $7.81
- Resistance Level
- SIBN $14.02
- PHAT $8.56
- Average True Range (ATR)
- SIBN 0.65
- PHAT 0.59
- MACD
- SIBN 0.06
- PHAT 0.22
- Stochastic Oscillator
- SIBN 47.22
- PHAT 38.28
About SIBN SI-BONE Inc.
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.